Share-Based Payments (Tables)

3 Months Ended

Mar. 31, 2026

Share-Based Payment Arrangement [Abstract]

Share-based compensation expense included in condensed consolidated statements of income

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:

	For the Three Months Ended March 31,
(In millions)	2026		2025
Research and development	$	34.8	$	32.1
Selling, general and administrative	53.0		52.0
Subtotal	87.8		84.1
Capitalized share-based compensation costs	(3.8)		(3.1)
Share-based compensation expense included in total cost and expense	84.0		81.0
Income tax effect	(16.5)		(16.0)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	67.5	$	65.0

Summary of share-based compensation expense associated with each of our share-based compensating programs

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:

	For the Three Months Ended March 31,
(In millions)	2026		2025
Time-vested restricted stock units	$	70.9	$	66.1
Performance stock units settled in stock	13.3		13.6
Employee stock purchase plan	3.6		3.5
Stock options	—		0.9
Subtotal	87.8		84.1
Capitalized share-based compensation costs	(3.8)		(3.1)
Share-based compensation expense included in total cost and expense	$	84.0	$	81.0